Read by QxMD icon Read

Glucocorticoid asthma

Sriroopreddy Ramireddy, P Raghuraman, Pradhyum Khandelwal, Jayanthi Abraham, C Sudandiradoss
Asthma, a chronic lung disease characterized by obstruction of airway passage is characterized by inflammation and hyperresponsiveness with increase in the number of eosinophils. Interleukin-13, plays a significant role in causing inflammation during an asthmatic attack by bronchial constriction. Mometasone, a glucocorticoid has been used as the first line of administration for people affected with asthma for almost a decade. However, in several cases, people treated with mometasone have faced systemic and local side effects...
August 2018: 3 Biotech
Seyed-Mohammad-Yousof Mostafavi-Pour-Manshadi, Nafiseh Naderi, Miriam Barrecheguren, Abolfazl Dehghan, Jean Bourbeau
Chronic obstructive pulmonary disease (COPD) is the most common fixed airflow limitation. Individuals may present with the features of both asthma and COPD called asthma-COPD overlap (ACO) with more severity and worse health-related quality of life than COPD or asthma. One of the promising biomarkers that could be used in clinical practice to differentiate ACO from COPD is fractional exhaled nitric oxide (FENO ). The role of Fractional exhaled nitric oxide (FENO ) in COPD/ACO remains unknown. This scoping review aims to investigate the role of FENO measurement to differentiate COPD from ACO, to anticipate disease severity/progression and treatment response...
August 1, 2018: COPD
Maria Teresa Río Ramírez, María Antonia Juretschke Moragues, Rocío Fernández González, Virginia Álvarez Rodríguez, Elena Aznar Andrés, Juan Pedro Zabaleta Camino, Rodolfo Romero Pareja, Andrés Esteban de la Torre
The aim of this study was to analyze whether FeNO levels in acute exacerbation of COPD (AECOPD) with hospital admission have better diagnostic value than eosinophilia in blood, and to evaluate its usefulness in predicting a better clinical response. An observational prospective study of patients with AECOPD was carried out. FeNO determinations were made on arrival at the emergency room (ER), at discharge and during stability 3-6 months after discharge. Co-morbidities, bronchodilators, inhaled (IGC) and systemic (SGC) glucocorticoids, eosinophils, systemic inflammation markers (procalcitonin, C-reactive protein), eosinophil cationic protein, and total IgE were collected...
July 31, 2018: COPD
Elena Goleva, Denise C Babineau, Michelle A Gill, Leisa P Jackson, Baomei Shao, Zheng Hu, Andrew H Liu, Cynthia M Visness, Christine A Sorkness, Donald Y M Leung, Alkis Togias, William W Busse
BACKGROUND: Variability in response to inhaled corticosteroids may result in less than optimal asthma control and development of biomarkers assessing therapeutic efficacy of corticosteroids is important. OBJECTIVE: To examine whether in vitro peripheral blood mononuclear cell (PBMC) responses to corticosteroids relate to the clinical inhaled corticosteroid response. METHODS: PBMC were collected from 125 children with asthma (6-17 years) at enrollment (Visit 0, V0) and after one year of bimonthly guidelines-based management visits (Visit 6, V6)...
July 27, 2018: Journal of Allergy and Clinical Immunology
George Bardsley, Peter Daley-Yates, Amanda Baines, Rodger Kempsford, Mathew Williams, Tony Mallon, Irene Braithwaite, Kylie Riddell, Shashidhar Joshi, Philippe Bareille, Richard Beasley, James Fingleton
BACKGROUND: Fluticasone furoate/Vilanterol trifenatate (FF/VI) is an inhaled corticosteroid/long-acting beta-agonist combination with a prolonged bronchodilator duration of action. We characterised the time-course of onset and offset of airway anti-inflammatory action of FF/VI, as assessed by fraction of exhaled nitric oxide (FeNO), and compared this to the bronchodilator duration of action. METHODS: A single-centre, randomised, double-blind, placebo-controlled, two-period, crossover study was undertaken in 28 steroid-naïve adults with asthma...
July 13, 2018: Respiratory Research
Javier Milara, Anselm Morell, Alfredo de Diego, Enrique Artigues, Esteban Morcillo, Julio Cortijo
BACKGROUND: The loss of corticosteroid efficacy is an important issue in severe asthma management, and may lead to poor asthma control and deterioration of airflow. Recent data indicates that MUC1 membrane mucin can mediate corticosteroid efficacy in chronic rhinosinusitis but the role of MUC1 in uncontrolled severe asthma is unknown. The objective was to analyze the previously unexplored role of MUC1 on corticosteroid efficacy in asthma. METHODS: MUC1 expression was evaluated by real time PCR in human bronchial epithelial cells (HBEC) and blood neutrophils from uncontrolled severe asthma (n=27) controlled mild asthma (n=16) and healthy subjects (n=13)...
July 6, 2018: Allergy
Valliappan Muthu, Inderpaul Singh Sehgal, Sahajal Dhooria, Amanjit Bal, Ritesh Agarwal
Allergic bronchopulmonary aspergillosis (ABPA) is a complex inflammatory lung disorder complicating bronchial asthma and cystic fibrosis. Although the condition responds to treatment with glucocorticoids and antifungal drugs, lack of timely recognition, and inadequate treatment of ABPA can lead to progressive lung damage. Uncommonly, long standing inflammation and bronchiectasis can also lead to the development of secondary amyloidosis. Herein, we report a case of ABPA, which presented as nephrotic syndrome and progressed rapidly to end-stage renal disease...
July 2018: Lung India: Official Organ of Indian Chest Society
Christopher F Rider, Mohammed O Altonsy, Mahmoud M Mostafa, Suharsh V Shah, Sarah Sasse, Martijn L Manson, Dong Yan, Carina Kärrman-Mårdh, Anna Miller-Larsson, Anthony N Gerber, Mark A Giembycz, Robert Newton
In asthma, the clinical efficacy of inhaled corticosteroids (ICSs) is enhanced by long-acting β 2 -adrenoceptor agonists (LABAs). ICSs, or more accurately, glucocorticoids, promote therapeutically relevant changes in gene expression, and, in primary human bronchial epithelial cells (pHBECs) and airway smooth muscle cells, this genomic effect can be enhanced by a LABA. Modeling this interaction in human bronchial airway epithelial BEAS-2B cells transfected with a 2× glucocorticoid response element (2×GRE)-driven luciferase reporter showed glucocorticoid-induced transcription to be enhanced 2- to 3-fold by LABA...
September 2018: Molecular Pharmacology
Shuhui Meng, Shuyu Chen, Ailin Tao
Asthma is a heterogeneous disease that consists of different phenotypes and endotypes, driven by different mechanistic pathways. An increasing number of genetic loci and single-nucleotide polymorphisms have been associated with therapeutic responses to asthma drugs. The purpose of this review is to focus on certain susceptibility genes, gene variants and typical therapeutic drugs of the glucocorticoid, leukotriene, histamine, and β2-adrenergic receptor pathways related to asthma. Pharmacogenomics can help us better understand the genetic basis of drug responses and better define new therapeutic targets to improve treatment effectiveness...
June 28, 2018: Current Drug Metabolism
William W Busse, Eric D Bateman, Arthur L Caplan, H William Kelly, Paul M O'Byrne, Klaus F Rabe, Vernon M Chinchilli
BACKGROUND: Safety concerns regarding long-acting β2 -agonists (LABAs) in asthma management were initially identified in a large postmarketing trial in which the risk of death was increased. In 2010, the Food and Drug Administration (FDA) mandated that the four companies marketing LABAs for asthma perform prospective, randomized, controlled trials comparing the safety of combination therapy with a LABA plus an inhaled glucocorticoid with that of an inhaled glucocorticoid alone in adolescents (12 to 17 years of age) and adults...
June 28, 2018: New England Journal of Medicine
Yuan Gao, Ming Zheng, Li Cui, Nan Chen, Yan-Ni Wang, Yu-Tao Zhan, Zhen-Gang Wang
PURPOSE: The objective of this study is to analyze the relationship between chronic rhino-sinusitis (CRS) and systemic symptoms in patients with IgG4-related disease (IgG4-RD). PATIENTS AND METHODS: The patients with IgG4-RD, confirmed by restrict association with clinical and histopathological manifestations between March 2013 and July 2016, were enrolled and followed-up for 1 year at the Tongren Hospital, Capital Medical University. The patients were divided into two groups: the case group included IgG4-RD patients with CRS confirmed by clinical and imaging, while the control group included IgG4-RD patients without CRS confirmed by clinical and imaging...
August 2018: European Archives of Oto-rhino-laryngology
Dietrich von Bonin, Sabine D Klein, Jana Würker, Eva Streit, Oliver Avianus, Christian Grah, Jörg Salomon, Ursula Wolf
BACKGROUND: Breathing retraining techniques have received increased attention in the management of asthma, because there is growing evidence of the usefulness of such methods in improving quality of life, reducing symptoms and reducing bronchodilator use. Our study investigated the effect of anthroposophic therapeutic speech (ATS), which uses sounds and syllabic rhythm to improve articulation, breathing and cardiorespiratory interaction, in patients with asthma in a real-life outpatient setting...
June 25, 2018: Trials
A Balasubramanian, S W Wade, R A Adler, K Saag, N Pannacciulli, J R Curtis
PURPOSE: We evaluated systemic glucocorticoid exposure and fracture among patients with newly-diagnosed inflammatory and immune-modulated conditions. METHODS: Using administrative data, inception cohorts of RA, asthma/COPD, IBD, MS, lupus, and sarcoidosis patients age 18-64 years with benefits coverage ≥12 months before diagnosis (1/1/2005-12/31/2012) were followed to clinical fracture, cancer diagnosis, or 12/31/2012. Glucocorticoid users were new to therapy...
June 20, 2018: Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research
Magda F Serra, Amanda C Cotias, Camila R R Pão, Julio B Daleprane, Patricia B Jurgilas, Gina C Couto, Edna A Anjos-Valotta, Renato S B Cordeiro, Vinicius F Carvalho, Patricia M R Silva, Marco A Martins
The importance of developing new animal models to assess the pathogenesis of glucocorticoid (GC)-insensitive asthma has been stressed. Because of the asthma-prone background of A/J mice, we hypothesized that asthma changes in these animals would be or become resistant to GCs under repeated exposures to an allergen. A/J mice were challenged with OVA for 2 or 4 consecutive d, starting on day 19 postsensitization. Oral dexamethasone or inhaled budesonide were given 1 h before challenge, and analyses were done 24 h after the last challenge...
August 1, 2018: Journal of Immunology: Official Journal of the American Association of Immunologists
Roxane Boivin, Amandine Vargas, Patricia Cano, Jean-Pierre Lavoie
Recurrent inflammation in severe equine asthma causes a remodeling of the airways leading to incompletely reversible airway obstruction. Despite the improvement of clinical signs and lung function with glucocorticoids (GC), inflammation, translated by an increased percentage of neutrophils, persists in the airways. Regulatory T cells (Treg) have been shown to have anti-inflammatory properties and play an important role in balancing the immune response by suppressing effector lymphocyte activity. However, interactions between Treg, neutrophils and glucocorticosteroids in vivo are unclear, particularly in asthma...
July 2018: Veterinary Immunology and Immunopathology
Diego J Maselli, Jay I Peters
No abstract text is available yet for this article.
June 19, 2018: Annals of Internal Medicine
Yun Liu, I Sophie T Bos, Tjitske A Oenema, Herman Meurs, Harm Maarsingh, Anna K H Hirsch
Budesonide is a hydrophobic glucocorticoid with high anti-inflammatory activity for the treatment of asthma, inflammatory bowel disease and rheumatoid arthritis. A micellar drug-delivery system based on lipid-DNA may provide a strategy to maximize its drug efficacy and reduce adverse effects. In this work, we report the use of lipid-DNA (UU11mer), featuring two hydrophobic alkyl chains and forming micelles at a comparatively low critical micelle concentration, to render budesonide water-soluble with a high loading capacity (LC)...
June 14, 2018: European Journal of Pharmaceutics and Biopharmaceutics
Jing Ren, Yong Sun, Gang Li, Xiao-Jue Zhu, Jin-Guo Cui
BACKGROUND: Bronchial asthma (BA) is a common chronic respiratory disease that has exhibited a rising global incidence in recent years. Glucocorticoids are used for the treatment of BA. Emerging evidence has demonstrated the roles of tumor necrosis factor (TNF-α), interleukin-8 (IL-8) and eosinophil cationic protein (ECP) in BA. The present study investigated whether TNF-α, IL-8 and ECP were associated with the clinical stages and severity of BA and the efficacy of glucocorticoids in the treatment of BA...
June 13, 2018: Respiratory Physiology & Neurobiology
Kayvan Saeedfar, Mehrdad Behmanesh, Esmaeil Mortaz, Mohammad Reza Masjedi
The response to glucocorticoids (GCs) therapy classifies severe refractory asthma (SRA) and mild asthma, so the glucocorticoid receptors (GCRs) gene expression may be involved in SRA pathogenesis. Thus, it is aimed to compare the expression levels of two GCR isoforms (GCRα and GCRβ) in SRA, mild asthmatics, and healthy controls. Total RNA was isolated from the peripheral blood mononuclear lymphocytes of 13 SRA patients, 14 mild asthma patients and 30 healthy volunteers. The expression levels of GCR isoforms were evaluated using quantitative real-time polymerase chain reaction (qRT-PCR)...
2018: Iranian Journal of Pharmaceutical Research: IJPR
(no author information available yet)
Eosinophilic chronic obstructive pulmonary disease (COPD) is characterised by a peripheral blood differential eosinophil count of 2% or more. This phenotype is found in roughly 40% of patients with COPD. These patients have an increased frequency of exacerbations, but benefit from inhaled glucocorticoids as part of a triple therapy regime. However, 30-40% of these patients continue to have significant exacerbations, meaning targeted therapy to reduce eosinophil counts could play a role in future therapy. Mepolizumab blocks interleukin-5 and has been associated with a decreased rate of exacerbation in eosinophilic asthma...
June 2018: Breathe
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"